ID   PHLC_CLOP1              Reviewed;         398 AA.
AC   Q0TV31; P15310; P94658; Q46246; Q46279; Q46280; Q46281; Q46282;
AC   Q57317; Q59303; Q59304; Q59305; Q59313; Q60121;
DT   31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 1.
DT   22-JUL-2015, entry version 70.
DE   RecName: Full=Phospholipase C;
DE            Short=PLC;
DE            EC=3.1.4.3;
DE   AltName: Full=Alpha-toxin;
DE   AltName: Full=Hemolysin;
DE   AltName: Full=Lecithinase;
DE   AltName: Full=Phosphatidylcholine cholinephosphohydrolase;
DE   Flags: Precursor;
GN   Name=plc; Synonyms=cpa; OrderedLocusNames=CPF_0042;
OS   Clostridium perfringens (strain ATCC 13124 / DSM 756 / JCM 1290 /
OS   NCIMB 6125 / NCTC 8237 / Type A).
OC   Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
OC   Clostridium.
OX   NCBI_TaxID=195103;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 29-39.
RX   PubMed=2540749; DOI=10.1016/0006-291X(89)91616-1;
RA   Okabe A., Shimizu T., Hayashi H.;
RT   "Cloning and sequencing of a phospholipase C gene of Clostridium
RT   perfringens.";
RL   Biochem. Biophys. Res. Commun. 160:33-39(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 29-53.
RX   PubMed=2536355;
RA   Titball R.W., Hunter S.E.C., Martin K.L., Morris B.C.,
RA   Shuttleworth A.D., Rubidge T., Anderson D.W., Kelly D.C.;
RT   "Molecular cloning and nucleotide sequence of the alpha-toxin
RT   (phospholipase C) of Clostridium perfringens.";
RL   Infect. Immun. 57:367-376(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND CHARACTERIZATION.
RX   PubMed=2536356;
RA   Tso J.Y., Siebel C.;
RT   "Cloning and expression of the phospholipase C gene from Clostridium
RT   perfringens and Clostridium bifermentans.";
RL   Infect. Immun. 57:468-476(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2546005; DOI=10.1111/j.1365-2958.1989.tb00183.x;
RA   Leslie D., Fairweather N., Pickard D., Dougan G., Kehoe M.;
RT   "Phospholipase C and haemolytic activities of Clostridium perfringens
RT   alpha-toxin cloned in Escherichia coli: sequence and homology with a
RT   Bacillus cereus phospholipase C.";
RL   Mol. Microbiol. 3:383-392(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 13124 / DSM 756 / JCM 1290 / NCIMB 6125 / NCTC 8237 / S
RC   107 / Type A;
RX   PubMed=16825665; DOI=10.1101/gr.5238106;
RA   Myers G.S.A., Rasko D.A., Cheung J.K., Ravel J., Seshadri R.,
RA   DeBoy R.T., Ren Q., Varga J., Awad M.M., Brinkac L.M., Daugherty S.C.,
RA   Haft D.H., Dodson R.J., Madupu R., Nelson W.C., Rosovitz M.J.,
RA   Sullivan S.A., Khouri H., Dimitrov G.I., Watkins K.L., Mulligan S.,
RA   Benton J., Radune D., Fisher D.J., Atkins H.S., Hiscox T., Jost B.H.,
RA   Billington S.J., Songer J.G., McClane B.A., Titball R.W., Rood J.I.,
RA   Melville S.B., Paulsen I.T.;
RT   "Skewed genomic variability in strains of the toxigenic bacterial
RT   pathogen, Clostridium perfringens.";
RL   Genome Res. 16:1031-1040(2006).
RN   [6]
RP   MUTAGENESIS OF HISTIDINE RESIDUES.
RX   PubMed=7868589;
RA   Nagahama M., Okagawa Y., Nakayama T., Nishioka E., Sakurai J.;
RT   "Site-directed mutagenesis of histidine residues in Clostridium
RT   perfringens alpha-toxin.";
RL   J. Bacteriol. 177:1179-1185(1995).
RN   [7]
RP   ACTIVITY AGAINST MOUSE ERYTHROCYTES, AND USE AS A VACCINE.
RX   PubMed=8581165;
RA   Ginter A., Williamson E.D., Dessy F., Coppe P., Bullifent H.,
RA   Howells A.M., Titball R.W.;
RT   "Molecular variation between the alpha-toxins from the type strain
RT   (NCTC 8237) and clinical isolates of Clostridium perfringens
RT   associated with disease in man and animals.";
RL   Microbiology 142:191-198(1996).
RN   [8]
RP   MUTAGENESIS OF ASP-297; TYR-303; TYR-335; TYR-359 AND ASP-364.
RX   PubMed=10931204; DOI=10.1046/j.1432-1327.2000.01588.x;
RA   Alape-Giron A., Flores-Diaz M., Guillouard I., Naylor C.E.,
RA   Titball R.W., Rucavado A., Lomonte B., Basak A.K., Gutierrez J.M.,
RA   Cole S.T., Thelestam M.;
RT   "Identification of residues critical for toxicity in Clostridium
RT   perfringens phospholipase C, the key toxin in gas gangrene.";
RL   Eur. J. Biochem. 267:5191-5197(2000).
RN   [9]
RP   MUTAGENESIS OF ASP-321; ASP-333 AND LYS-358.
RX   PubMed=11147832; DOI=10.1006/abbi.2000.2065;
RA   Walker N., Holley J., Naylor C.E., Flores-Diaz M., Alape-Giron A.,
RA   Carter G., Carr F.J., Thelestam M., Keyte M., Moss D.S., Basak A.K.,
RA   Miller J., Titball R.W.;
RT   "Identification of residues in the carboxy-terminal domain of
RT   Clostridium perfringens alpha-toxin (phospholipase C) which are
RT   required for its biological activities.";
RL   Arch. Biochem. Biophys. 384:24-30(2000).
RN   [10]
RP   MUTAGENESIS OF ASP-297; TYR-359 AND PHE-362.
RX   PubMed=11334886; DOI=10.1016/S0014-5793(01)02385-7;
RA   Jepson M., Bullifent H.L., Crane D.T., Flores-Diaz M., Alape-Giron A.,
RA   Jayasekera P., Lingard B., Moss D.S., Titball R.W.;
RT   "Tyrosine 331 and phenylalanine 334 in Clostridium perfringens alpha-
RT   toxin are essential for cytotoxic activity.";
RL   FEBS Lett. 495:172-177(2001).
RN   [11]
RP   CHARACTERIZATION.
RX   PubMed=2497921; DOI=10.1111/j.1476-5381.1989.tb11931.x;
RA   Fujii Y., Sakurai J.;
RT   "Contraction of the rat isolated aorta caused by Clostridium
RT   perfringens alpha toxin (phospholipase C): evidence for the
RT   involvement of arachidonic acid metabolism.";
RL   Br. J. Pharmacol. 97:119-124(1989).
RN   [12]
RP   IMPORTANCE OF ZINC.
RX   PubMed=2111259;
RA   Titball R.W., Rubidge T.;
RT   "The role of histidine residues in the alpha toxin of Clostridium
RT   perfringens.";
RL   FEMS Microbiol. Lett. 56:261-265(1990).
RN   [13]
RP   SIMILARITY OF C-TERMINAL DOMAIN TO LIPOXYGENASES AND C-TERMINAL
RP   TRUNCATION.
RX   PubMed=1902199;
RA   Titball R.W., Leslie D.L., Harvey S., Kelly D.C.;
RT   "Hemolytic and sphingomyelinase activities of Clostridium perfringens
RT   alpha-toxin are dependent on a domain homologous to that of an enzyme
RT   from the human arachidonic acid pathway.";
RL   Infect. Immun. 59:1872-1874(1991).
RN   [14]
RP   REVIEW.
RX   PubMed=16887662; DOI=10.1006/anae.1999.0191;
RA   Titball R.W., Naylor C.E., Basak A.K.;
RT   "The Clostridium perfringens alpha-toxin.";
RL   Anaerobe 5:51-64(1999).
RN   [15]
RP   REVIEW.
RX   PubMed=11008117; DOI=10.1016/S1286-4579(00)01281-8;
RA   Jepson M., Titball R.W.;
RT   "Structure and function of clostridial phospholipases C.";
RL   Microbes Infect. 2:1277-1284(2000).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 29-398 OF THE CALCIUM-BOUND
RP   CLOSED FORM.
RX   PubMed=10610794; DOI=10.1006/jmbi.1999.3279;
RA   Naylor C.E., Jepson M., Crane D.T., Titball R.W., Miller J.,
RA   Basak A.K., Bolgiano B.;
RT   "Characterisation of the calcium-binding C-terminal domain of
RT   Clostridium perfringens alpha-toxin.";
RL   J. Mol. Biol. 294:757-770(1999).
CC   -!- FUNCTION: Bacterial hemolysins are exotoxins that attack blood
CC       cell membranes and cause cell rupture. Constitutes an essential
CC       virulence factor in gas gangrene. Binds to eukaryotic membranes
CC       where it hydrolyzes both phosphatidylcholine and sphingomyelin.
CC       The diacylglycerol produced can activate both the arachidonic acid
CC       pathway, leading to modulation of the inflammatory response
CC       cascade and thrombosis, and protein kinase C, leading to
CC       activation of eukaryotic phospholipases and further membrane
CC       damage. Acts on human and mouse erythrocytes, but not on rabbit or
CC       horse erythrocytes.
CC   -!- CATALYTIC ACTIVITY: A phosphatidylcholine + H(2)O = 1,2-diacyl-sn-
CC       glycerol + phosphocholine.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC       Note=Binds 3 Ca(2+) ions per subunit.;
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 3 Zn(2+) ions per subunit.;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- DOMAIN: The protein is composed of 2 domains; the N-terminal
CC       domain contains the phospholipase C active site (PLC), in a cleft
CC       which is also occupied by the 3 zinc ions. The C-terminal domain
CC       is a putative phospholipid-recognition domain, which shows
CC       structural homology with phospholipid-binding C2-like domains from
CC       a range of eukaryotic proteins. The ability to bind membrane
CC       phospholipids in a Ca(2+) dependent manner and toxicity is
CC       conferred by this C-terminal domain, which also contributes to the
CC       sphingomyelinase activity.
CC   -!- BIOTECHNOLOGY: Vaccination of mice with a fragment (residues 275-
CC       398) protects them against a subsequent challenge with purified
CC       alpha-toxin.
CC   -!- MISCELLANEOUS: Two main forms of alpha-toxin can be purified from
CC       C.perfringens; a major form with a pI of 5.48, and a minor form
CC       with a pI of 5.6. Both are equally active. Variations seen in PLC
CC       activity between different strains may be due to transcriptional
CC       regulation.
CC   -!- MISCELLANEOUS: Mutating residues 303 or 359 of the C.perfringens
CC       toxin to match those found in C.bifermentans (301 and 358
CC       respectively) reduces toxicity considerably.
CC   -!- SIMILARITY: Belongs to the bacterial zinc-metallophospholipase C
CC       family. {ECO:0000255|PROSITE-ProRule:PRU00678}.
CC   -!- SIMILARITY: Contains 1 PLAT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00152}.
CC   -!- SIMILARITY: Contains 1 Zn-dependent PLC domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00678}.
CC   -!- WEB RESOURCE: Name=Worthington enzyme manual;
CC       URL="http://www.worthington-biochem.com/PLC/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M24904; AAA23272.1; -; Genomic_DNA.
DR   EMBL; X13608; CAA31943.1; -; Genomic_DNA.
DR   EMBL; CP000246; ABG84486.1; -; Genomic_DNA.
DR   PIR; A30565; A30565.
DR   RefSeq; WP_011590041.1; NC_008261.1.
DR   PDB; 1QM6; X-ray; 2.50 A; A/B=29-398.
DR   PDB; 1QMD; X-ray; 2.20 A; A/B=29-398.
DR   PDB; 2WXT; X-ray; 2.00 A; A=29-398.
DR   PDB; 2WXU; X-ray; 1.80 A; A=29-398.
DR   PDB; 2WY6; X-ray; 3.20 A; A/B/C=29-398.
DR   PDBsum; 1QM6; -.
DR   PDBsum; 1QMD; -.
DR   PDBsum; 2WXT; -.
DR   PDBsum; 2WXU; -.
DR   PDBsum; 2WY6; -.
DR   ProteinModelPortal; Q0TV31; -.
DR   SMR; Q0TV31; 29-398.
DR   STRING; 195103.CPF_0042; -.
DR   EnsemblBacteria; ABG84486; ABG84486; CPF_0042.
DR   KEGG; cpf:CPF_0042; -.
DR   PATRIC; 19482373; VBICloPer106549_0034.
DR   KO; K16619; -.
DR   OMA; DHFWDPD; -.
DR   OrthoDB; EOG6PS5WX; -.
DR   BioCyc; CPER195103:GHAW-45-MONOMER; -.
DR   EvolutionaryTrace; Q0TV31; -.
DR   Proteomes; UP000001823; Chromosome.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016787; F:hydrolase activity; IDA:CACAO.
DR   GO; GO:0034480; F:phosphatidylcholine phospholipase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0044179; P:hemolysis in other organism; IDA:CACAO.
DR   GO; GO:0008152; P:metabolic process; IDA:GOC.
DR   GO; GO:0009405; P:pathogenesis; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.575.10; -; 1.
DR   Gene3D; 2.60.60.20; -; 1.
DR   InterPro; IPR008976; Lipase_LipOase.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR008947; PLipase_C/P1_nuclease.
DR   InterPro; IPR001531; PLipaseC_domain.
DR   InterPro; IPR029002; PLPC/GPLD1.
DR   Pfam; PF01477; PLAT; 1.
DR   Pfam; PF00882; Zn_dep_PLPC; 1.
DR   PRINTS; PR00479; PRPHPHLPASEC.
DR   ProDom; PD003946; PLipaseC_Zn-bd_prok; 1.
DR   SMART; SM00770; Zn_dep_PLPC; 1.
DR   SUPFAM; SSF48537; SSF48537; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   PROSITE; PS50095; PLAT; 1.
DR   PROSITE; PS00384; PROKAR_ZN_DEPEND_PLPC_1; 1.
DR   PROSITE; PS51346; PROKAR_ZN_DEPEND_PLPC_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Cytolysis;
KW   Direct protein sequencing; Hemolysis; Hydrolase; Metal-binding;
KW   Secreted; Signal; Toxin; Virulence; Zinc.
FT   SIGNAL        1     28       {ECO:0000269|PubMed:2536355,
FT                                ECO:0000269|PubMed:2540749}.
FT   CHAIN        29    398       Phospholipase C.
FT                                /FTId=PRO_0000259456.
FT   DOMAIN       29    278       Zn-dependent PLC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00678}.
FT   DOMAIN      284    398       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   REGION      275    283       Linker.
FT   METAL        29     29       Zinc 1.
FT   METAL        39     39       Zinc 1.
FT   METAL        84     84       Zinc 3.
FT   METAL        96     96       Zinc 3.
FT   METAL       154    154       Zinc 3.
FT   METAL       158    158       Zinc 1.
FT   METAL       158    158       Zinc 3.
FT   METAL       164    164       Zinc 2. {ECO:0000305}.
FT   METAL       176    176       Zinc 2. {ECO:0000305}.
FT   METAL       180    180       Zinc 2. {ECO:0000305}.
FT   METAL       297    297       Calcium 1.
FT   METAL       299    299       Calcium 1; via carbonyl oxygen.
FT   METAL       300    300       Calcium 3.
FT   METAL       301    301       Calcium 3.
FT   METAL       321    321       Calcium 2.
FT   METAL       322    322       Calcium 2.
FT   METAL       324    324       Calcium 2; via carbonyl oxygen.
FT   METAL       325    325       Calcium 3.
FT   METAL       326    326       Calcium 2.
FT   METAL       326    326       Calcium 3.
FT   METAL       364    364       Calcium 1.
FT   METAL       365    365       Calcium 1; via carbonyl oxygen.
FT   MUTAGEN     278    398       Missing: Loss of sphingomyelinase,
FT                                hemolytic activity and lethality.
FT                                {ECO:0000269|PubMed:7868589}.
FT   MUTAGEN     297    297       D->Y: Binds less Ca(2+), small decrease
FT                                in PLC, sphingomyelinase and myotoxicity,
FT                                increased hemolytic and cytotoxic
FT                                activities. {ECO:0000269|PubMed:10931204,
FT                                ECO:0000269|PubMed:11334886}.
FT   MUTAGEN     303    303       Y->F,N: Increased dependence of PLC on
FT                                Ca(2+). Dramatically decreases hemolytic,
FT                                cytotoxic and myotoxic activities.
FT                                {ECO:0000269|PubMed:10931204}.
FT   MUTAGEN     321    321       D->S: Reduces affinity for Ca(2+),
FT                                decreases toxin activity.
FT                                {ECO:0000269|PubMed:11147832}.
FT   MUTAGEN     333    333       D->G: Decreases toxin activity in vivo
FT                                and against aggregated substrates in
FT                                vitro. May destabilize interactions
FT                                between the N and C-terminal domains.
FT                                {ECO:0000269|PubMed:11147832}.
FT   MUTAGEN     335    335       Y->F: Dramatically decreases hemolytic
FT                                and cytotoxic activities.
FT                                {ECO:0000269|PubMed:10931204}.
FT   MUTAGEN     358    358       K->E: Decreases toxin activity in vivo
FT                                and against aggregated substrates in
FT                                vitro. {ECO:0000269|PubMed:11147832}.
FT   MUTAGEN     359    359       Y->F,L: Dramatically decreases hemolytic
FT                                and cytotoxic activities.
FT                                {ECO:0000269|PubMed:10931204,
FT                                ECO:0000269|PubMed:11334886}.
FT   MUTAGEN     362    362       F->I: Dramatically decreases
FT                                sphingomyelinase, cytotoxicity and
FT                                hemolytic and myotoxic activities.
FT                                {ECO:0000269|PubMed:11334886}.
FT   MUTAGEN     364    364       D->N: Increased dependence of PLC on
FT                                Ca(2+). Dramatically decreases hemolytic,
FT                                cytotoxic and myotoxic activities.
FT                                {ECO:0000269|PubMed:10931204}.
FT   CONFLICT     17     17       S -> T (in Ref. 3). {ECO:0000305}.
FT   TURN         33     35       {ECO:0000244|PDB:2WXU}.
FT   HELIX        38     53       {ECO:0000244|PDB:2WXU}.
FT   HELIX        60     71       {ECO:0000244|PDB:2WXU}.
FT   HELIX        73     81       {ECO:0000244|PDB:2WXU}.
FT   HELIX        82     84       {ECO:0000244|PDB:2WXU}.
FT   HELIX        94     96       {ECO:0000244|PDB:2WXU}.
FT   HELIX       102    107       {ECO:0000244|PDB:1QMD}.
FT   STRAND      108    112       {ECO:0000244|PDB:1QMD}.
FT   TURN        113    115       {ECO:0000244|PDB:2WXU}.
FT   HELIX       122    138       {ECO:0000244|PDB:2WXU}.
FT   HELIX       142    159       {ECO:0000244|PDB:2WXU}.
FT   TURN        163    167       {ECO:0000244|PDB:2WXU}.
FT   TURN        170    172       {ECO:0000244|PDB:2WXU}.
FT   HELIX       175    186       {ECO:0000244|PDB:2WXU}.
FT   HELIX       187    190       {ECO:0000244|PDB:2WXU}.
FT   HELIX       202    209       {ECO:0000244|PDB:2WXU}.
FT   HELIX       213    234       {ECO:0000244|PDB:2WXU}.
FT   STRAND      237    240       {ECO:0000244|PDB:2WY6}.
FT   HELIX       242    273       {ECO:0000244|PDB:2WXU}.
FT   TURN        277    280       {ECO:0000244|PDB:2WXT}.
FT   STRAND      285    292       {ECO:0000244|PDB:2WXU}.
FT   STRAND      302    310       {ECO:0000244|PDB:2WXU}.
FT   STRAND      315    319       {ECO:0000244|PDB:2WXU}.
FT   STRAND      332    338       {ECO:0000244|PDB:2WXU}.
FT   HELIX       346    348       {ECO:0000244|PDB:2WXU}.
FT   STRAND      349    357       {ECO:0000244|PDB:2WXU}.
FT   STRAND      359    362       {ECO:0000244|PDB:2WXU}.
FT   STRAND      368    375       {ECO:0000244|PDB:2WXU}.
FT   STRAND      378    384       {ECO:0000244|PDB:2WXU}.
FT   STRAND      394    398       {ECO:0000244|PDB:2WXU}.
SQ   SEQUENCE   398 AA;  45476 MW;  4A36E7E2A7139724 CRC64;
     MKRKICKALI CAALATSLWA GASTKVYAWD GKIDGTGTHA MIVTQGVSIL ENDLSKNEPE
     SVRKNLEILK ENMHELQLGS TYPDYDKNAY DLYQDHFWDP DTDNNFSKDN SWYLAYSIPD
     TGESQIRKFS ALARYEWQRG NYKQATFYLG EAMHYFGDID TPYHPANVTA VDSAGHVKFE
     TFAEERKEQY KINTAGCKTN EAFYTDILKN KDFNAWSKEY ARGFAKTGKS IYYSHASMSH
     SWDDWDYAAK VTLANSQKGT AGYIYRFLHD VSEGNDPSVG KNVKELVAYI STSGEKDAGT
     DDYMYFGIKT KDGKTQEWEM DNPGNDFMTG SKDTYTFKLK DENLKIDDIQ NMWIRKRKYT
     AFSDAYKPEN IKIIANGKVV VDKDINEWIS GNSTYNIK
//
